Long term population impact of seven-valent pneumococcal conjugate vaccine with a “3 + 0″ schedule—How do “2 + 1″ and “3 + 1″ schedules compare?
Abstract Introduction Significant reductions in invasive pneumococcal disease (IPD) following 7-valent pneumococcal conjugate vaccine (7vPCV) are well documented, but population-level data comparing different schedules are sparse. We compared data from long-term stable surveillance in one Australian...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2015-06, Vol.33 (28), p.3234-3241 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3241 |
|---|---|
| container_issue | 28 |
| container_start_page | 3234 |
| container_title | Vaccine |
| container_volume | 33 |
| creator | Lowbridge, Christopher McIntyre, Peter B Gilmour, Robin Chiu, Clayton Seale, Holly Ferson, Mark J Gilbert, Gwendolyn L |
| description | Abstract Introduction Significant reductions in invasive pneumococcal disease (IPD) following 7-valent pneumococcal conjugate vaccine (7vPCV) are well documented, but population-level data comparing different schedules are sparse. We compared data from long-term stable surveillance in one Australian region (3 primary doses (3 + 0) schedule) with similar data from England and Wales (2 + 1 schedule) and the United States (3 + 1 schedule). Methods Incidence rate ratios (IRRs) for all, vaccine type, and non-vaccine type IPD were calculated by age-group, using comparable case definitions and time periods post 7vPCV introduction. Results At baseline, the % of IPD due to 7vPCV serotypes (VT) disease in children |
| doi_str_mv | 10.1016/j.vaccine.2015.04.079 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1687351499</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X15005654</els_id><sourcerecordid>1687351499</sourcerecordid><originalsourceid>FETCH-LOGICAL-c518t-37262891bdd89ff33c457659936f62d50c0aacb264330a8438f4c6127079b86e3</originalsourceid><addsrcrecordid>eNqFks9u1DAQxi0EosvCI4AscUFCCf4TO8mFqqqAIq3EAZC4WV5n0npJ7GAnW_W2D8ER8RK80T4JjnYLqBdOPsxvPs983yD0lJKcEipfbfKtNsY6yBmhIidFTsr6HlrQquQZE7S6jxaEySIrKPlygh7FuCGECE7rh-iEiVowIcoF-rny7hKPEHo8-GHq9Gi9w7YftBmxb3GELbhsqztwIx4cTL033hjdYePdZrrUI-DjIPjajldY4_3uB8cvMdnvfuForqCZOtjvvl_4a9z4ucpSlc5V7Zpbmv5LxySeJghw-hg9aHUX4cnxXaLPb998Or_IVh_evT8_W2UmbTpmvGSSVTVdN01Vty3nphClFHXNZStZI4ghWpt1soNzoquCV21hJGVl8mxdSeBL9OKgOwT_bYI4qt5GA12nHfgpKiqTrYIWSXGJnt9BN34KLk03U5JUFSEyUeJAmeBjDNCqIdhehxtFiZoDVBt19E3NASpSqDRM6nt2VJ_WPTR_um4TS8DpAYBkx9ZCUNFYcAYaG8CMqvH2v1-8vqNgOutsyvQr3ED8u42KTBH1cb6i-YioSPcjRcF_A0_SyAE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1686088006</pqid></control><display><type>article</type><title>Long term population impact of seven-valent pneumococcal conjugate vaccine with a “3 + 0″ schedule—How do “2 + 1″ and “3 + 1″ schedules compare?</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Lowbridge, Christopher ; McIntyre, Peter B ; Gilmour, Robin ; Chiu, Clayton ; Seale, Holly ; Ferson, Mark J ; Gilbert, Gwendolyn L</creator><creatorcontrib>Lowbridge, Christopher ; McIntyre, Peter B ; Gilmour, Robin ; Chiu, Clayton ; Seale, Holly ; Ferson, Mark J ; Gilbert, Gwendolyn L</creatorcontrib><description>Abstract Introduction Significant reductions in invasive pneumococcal disease (IPD) following 7-valent pneumococcal conjugate vaccine (7vPCV) are well documented, but population-level data comparing different schedules are sparse. We compared data from long-term stable surveillance in one Australian region (3 primary doses (3 + 0) schedule) with similar data from England and Wales (2 + 1 schedule) and the United States (3 + 1 schedule). Methods Incidence rate ratios (IRRs) for all, vaccine type, and non-vaccine type IPD were calculated by age-group, using comparable case definitions and time periods post 7vPCV introduction. Results At baseline, the % of IPD due to 7vPCV serotypes (VT) disease in children <5 years was 88% in Greater Sydney (GS), 83% in the United States (US), and 74% in England and Wales (E&W). IRR for VT IPD <5 years in GS was 0.05 (0.02–0.09), for ≥65 years was 0.15 (0.12–0.19) and for all ages 0.12 (0.10–0.13). In the US, IRR for VT IPD was lower in each age group, and for all ages the 95% CI of the IRR (0.06 (0.05–0.07)), did not overlap with GS or E&W (0.14 (0.11–0.18)). In contrast, the IRR for IPD due to any serotype did not differ between sites for any age group or overall. Conclusions Differences in direct and indirect reductions in VT IPD with a “3 + 0″ 7vPCV schedule versus “2 + 1″ or “3 + 1″ were small. All 3 countries moved to 13vPCV by 2011; data post 13vPCV will be important to assess IPD impact using more similar baseline incidence and comparison periods.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2015.04.079</identifier><identifier>PMID: 25952557</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adolescent ; Adult ; Age Factors ; Aged ; Allergy and Immunology ; Australia - epidemiology ; Child ; Child, Preschool ; Comparison ; Conjugate ; England - epidemiology ; Epidemiological Monitoring ; Heptavalent Pneumococcal Conjugate Vaccine - administration & dosage ; Humans ; Immunization ; Immunization Schedule ; Incidence ; Infant ; Male ; Medical research ; Meningitis ; Middle Aged ; Pneumococcal ; Pneumococcal Infections - epidemiology ; Pneumococcal Infections - prevention & control ; Pneumonia ; Schedule ; Serogroup ; Time Factors ; United States - epidemiology ; Vaccination ; Vaccines ; Wales - epidemiology ; Young Adult</subject><ispartof>Vaccine, 2015-06, Vol.33 (28), p.3234-3241</ispartof><rights>Elsevier Ltd</rights><rights>2015 Elsevier Ltd</rights><rights>Copyright © 2015 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Jun 22, 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c518t-37262891bdd89ff33c457659936f62d50c0aacb264330a8438f4c6127079b86e3</citedby><cites>FETCH-LOGICAL-c518t-37262891bdd89ff33c457659936f62d50c0aacb264330a8438f4c6127079b86e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X15005654$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25952557$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lowbridge, Christopher</creatorcontrib><creatorcontrib>McIntyre, Peter B</creatorcontrib><creatorcontrib>Gilmour, Robin</creatorcontrib><creatorcontrib>Chiu, Clayton</creatorcontrib><creatorcontrib>Seale, Holly</creatorcontrib><creatorcontrib>Ferson, Mark J</creatorcontrib><creatorcontrib>Gilbert, Gwendolyn L</creatorcontrib><title>Long term population impact of seven-valent pneumococcal conjugate vaccine with a “3 + 0″ schedule—How do “2 + 1″ and “3 + 1″ schedules compare?</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Abstract Introduction Significant reductions in invasive pneumococcal disease (IPD) following 7-valent pneumococcal conjugate vaccine (7vPCV) are well documented, but population-level data comparing different schedules are sparse. We compared data from long-term stable surveillance in one Australian region (3 primary doses (3 + 0) schedule) with similar data from England and Wales (2 + 1 schedule) and the United States (3 + 1 schedule). Methods Incidence rate ratios (IRRs) for all, vaccine type, and non-vaccine type IPD were calculated by age-group, using comparable case definitions and time periods post 7vPCV introduction. Results At baseline, the % of IPD due to 7vPCV serotypes (VT) disease in children <5 years was 88% in Greater Sydney (GS), 83% in the United States (US), and 74% in England and Wales (E&W). IRR for VT IPD <5 years in GS was 0.05 (0.02–0.09), for ≥65 years was 0.15 (0.12–0.19) and for all ages 0.12 (0.10–0.13). In the US, IRR for VT IPD was lower in each age group, and for all ages the 95% CI of the IRR (0.06 (0.05–0.07)), did not overlap with GS or E&W (0.14 (0.11–0.18)). In contrast, the IRR for IPD due to any serotype did not differ between sites for any age group or overall. Conclusions Differences in direct and indirect reductions in VT IPD with a “3 + 0″ 7vPCV schedule versus “2 + 1″ or “3 + 1″ were small. All 3 countries moved to 13vPCV by 2011; data post 13vPCV will be important to assess IPD impact using more similar baseline incidence and comparison periods.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Allergy and Immunology</subject><subject>Australia - epidemiology</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Comparison</subject><subject>Conjugate</subject><subject>England - epidemiology</subject><subject>Epidemiological Monitoring</subject><subject>Heptavalent Pneumococcal Conjugate Vaccine - administration & dosage</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunization Schedule</subject><subject>Incidence</subject><subject>Infant</subject><subject>Male</subject><subject>Medical research</subject><subject>Meningitis</subject><subject>Middle Aged</subject><subject>Pneumococcal</subject><subject>Pneumococcal Infections - epidemiology</subject><subject>Pneumococcal Infections - prevention & control</subject><subject>Pneumonia</subject><subject>Schedule</subject><subject>Serogroup</subject><subject>Time Factors</subject><subject>United States - epidemiology</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Wales - epidemiology</subject><subject>Young Adult</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFks9u1DAQxi0EosvCI4AscUFCCf4TO8mFqqqAIq3EAZC4WV5n0npJ7GAnW_W2D8ER8RK80T4JjnYLqBdOPsxvPs983yD0lJKcEipfbfKtNsY6yBmhIidFTsr6HlrQquQZE7S6jxaEySIrKPlygh7FuCGECE7rh-iEiVowIcoF-rny7hKPEHo8-GHq9Gi9w7YftBmxb3GELbhsqztwIx4cTL033hjdYePdZrrUI-DjIPjajldY4_3uB8cvMdnvfuForqCZOtjvvl_4a9z4ucpSlc5V7Zpbmv5LxySeJghw-hg9aHUX4cnxXaLPb998Or_IVh_evT8_W2UmbTpmvGSSVTVdN01Vty3nphClFHXNZStZI4ghWpt1soNzoquCV21hJGVl8mxdSeBL9OKgOwT_bYI4qt5GA12nHfgpKiqTrYIWSXGJnt9BN34KLk03U5JUFSEyUeJAmeBjDNCqIdhehxtFiZoDVBt19E3NASpSqDRM6nt2VJ_WPTR_um4TS8DpAYBkx9ZCUNFYcAYaG8CMqvH2v1-8vqNgOutsyvQr3ED8u42KTBH1cb6i-YioSPcjRcF_A0_SyAE</recordid><startdate>20150622</startdate><enddate>20150622</enddate><creator>Lowbridge, Christopher</creator><creator>McIntyre, Peter B</creator><creator>Gilmour, Robin</creator><creator>Chiu, Clayton</creator><creator>Seale, Holly</creator><creator>Ferson, Mark J</creator><creator>Gilbert, Gwendolyn L</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20150622</creationdate><title>Long term population impact of seven-valent pneumococcal conjugate vaccine with a “3 + 0″ schedule—How do “2 + 1″ and “3 + 1″ schedules compare?</title><author>Lowbridge, Christopher ; McIntyre, Peter B ; Gilmour, Robin ; Chiu, Clayton ; Seale, Holly ; Ferson, Mark J ; Gilbert, Gwendolyn L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c518t-37262891bdd89ff33c457659936f62d50c0aacb264330a8438f4c6127079b86e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Allergy and Immunology</topic><topic>Australia - epidemiology</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Comparison</topic><topic>Conjugate</topic><topic>England - epidemiology</topic><topic>Epidemiological Monitoring</topic><topic>Heptavalent Pneumococcal Conjugate Vaccine - administration & dosage</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunization Schedule</topic><topic>Incidence</topic><topic>Infant</topic><topic>Male</topic><topic>Medical research</topic><topic>Meningitis</topic><topic>Middle Aged</topic><topic>Pneumococcal</topic><topic>Pneumococcal Infections - epidemiology</topic><topic>Pneumococcal Infections - prevention & control</topic><topic>Pneumonia</topic><topic>Schedule</topic><topic>Serogroup</topic><topic>Time Factors</topic><topic>United States - epidemiology</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Wales - epidemiology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lowbridge, Christopher</creatorcontrib><creatorcontrib>McIntyre, Peter B</creatorcontrib><creatorcontrib>Gilmour, Robin</creatorcontrib><creatorcontrib>Chiu, Clayton</creatorcontrib><creatorcontrib>Seale, Holly</creatorcontrib><creatorcontrib>Ferson, Mark J</creatorcontrib><creatorcontrib>Gilbert, Gwendolyn L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lowbridge, Christopher</au><au>McIntyre, Peter B</au><au>Gilmour, Robin</au><au>Chiu, Clayton</au><au>Seale, Holly</au><au>Ferson, Mark J</au><au>Gilbert, Gwendolyn L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long term population impact of seven-valent pneumococcal conjugate vaccine with a “3 + 0″ schedule—How do “2 + 1″ and “3 + 1″ schedules compare?</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2015-06-22</date><risdate>2015</risdate><volume>33</volume><issue>28</issue><spage>3234</spage><epage>3241</epage><pages>3234-3241</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>Abstract Introduction Significant reductions in invasive pneumococcal disease (IPD) following 7-valent pneumococcal conjugate vaccine (7vPCV) are well documented, but population-level data comparing different schedules are sparse. We compared data from long-term stable surveillance in one Australian region (3 primary doses (3 + 0) schedule) with similar data from England and Wales (2 + 1 schedule) and the United States (3 + 1 schedule). Methods Incidence rate ratios (IRRs) for all, vaccine type, and non-vaccine type IPD were calculated by age-group, using comparable case definitions and time periods post 7vPCV introduction. Results At baseline, the % of IPD due to 7vPCV serotypes (VT) disease in children <5 years was 88% in Greater Sydney (GS), 83% in the United States (US), and 74% in England and Wales (E&W). IRR for VT IPD <5 years in GS was 0.05 (0.02–0.09), for ≥65 years was 0.15 (0.12–0.19) and for all ages 0.12 (0.10–0.13). In the US, IRR for VT IPD was lower in each age group, and for all ages the 95% CI of the IRR (0.06 (0.05–0.07)), did not overlap with GS or E&W (0.14 (0.11–0.18)). In contrast, the IRR for IPD due to any serotype did not differ between sites for any age group or overall. Conclusions Differences in direct and indirect reductions in VT IPD with a “3 + 0″ 7vPCV schedule versus “2 + 1″ or “3 + 1″ were small. All 3 countries moved to 13vPCV by 2011; data post 13vPCV will be important to assess IPD impact using more similar baseline incidence and comparison periods.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>25952557</pmid><doi>10.1016/j.vaccine.2015.04.079</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2015-06, Vol.33 (28), p.3234-3241 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1687351499 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adolescent Adult Age Factors Aged Allergy and Immunology Australia - epidemiology Child Child, Preschool Comparison Conjugate England - epidemiology Epidemiological Monitoring Heptavalent Pneumococcal Conjugate Vaccine - administration & dosage Humans Immunization Immunization Schedule Incidence Infant Male Medical research Meningitis Middle Aged Pneumococcal Pneumococcal Infections - epidemiology Pneumococcal Infections - prevention & control Pneumonia Schedule Serogroup Time Factors United States - epidemiology Vaccination Vaccines Wales - epidemiology Young Adult |
| title | Long term population impact of seven-valent pneumococcal conjugate vaccine with a “3 + 0″ schedule—How do “2 + 1″ and “3 + 1″ schedules compare? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T21%3A46%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long%20term%20population%20impact%20of%20seven-valent%20pneumococcal%20conjugate%20vaccine%20with%20a%20%E2%80%9C3%20+%200%E2%80%B3%20schedule%E2%80%94How%20do%20%E2%80%9C2%20+%201%E2%80%B3%20and%20%E2%80%9C3%20+%201%E2%80%B3%20schedules%20compare?&rft.jtitle=Vaccine&rft.au=Lowbridge,%20Christopher&rft.date=2015-06-22&rft.volume=33&rft.issue=28&rft.spage=3234&rft.epage=3241&rft.pages=3234-3241&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2015.04.079&rft_dat=%3Cproquest_cross%3E1687351499%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1686088006&rft_id=info:pmid/25952557&rft_els_id=S0264410X15005654&rfr_iscdi=true |